secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001558370-23-012903
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Q2 net revenue $58.7M (+81% QoQ); CIMERLI sales quadruple to $26.7M
---------------------------------------------------------------------------

- Net revenue $58.7M, up 81% from prior quarter; UDENYCA $31.7M, CIMERLI $26.7M.
- Net loss $42.9M ($0.49 diluted EPS); non-GAAP net loss $32.8M ($0.38).
- Launched UDENYCA autoinjector in May, YUSIMRY (Humira biosimilar) in July.
- Planned merger with Surface Oncology expected to close after Sep 7 shareholder meeting.
- FDA inspections for toripalimab ongoing; potential approval and launch H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023012903/0001558370-23-012903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023012903/chrs-20230802x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-012903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer